Galera Therapeutics, Inc. is a clinical-stage biotechnology company, headquartered in Malvern, PA, focused on the development of breakthrough drugs targeting oxygen metabolic pathways. The Company's lead compounds are highly selective small molecule dismutase mimetics that closely mimic the activity of the human superoxide dismutase enzymes. While the biology of the superoxide dismutase family suggests a broad range of potential applications, Galera is initially focusing its development on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/11/12 | $11,000,000 | Series A |
Correlation Ventures Novartis Venture Funds | undisclosed |
| 10/14/15 | $37,000,000 | Series B |
Correlation Ventures Galera Angels Novartis Venture Funds Novo Ventures | undisclosed |
| 02/03/16 | $5,000,000 | Series B | ||
| 11/28/16 | $15,000,000 | Series B |
Sofinnova Ventures | undisclosed |
| 09/20/18 | $150,000,000 | Series C |
Adage Capital Management Clarus Ventures  Correlation Ventures Galera Angels HBM Healthcare Investments Nan Fung New Enterprise Associates Novartis Venture Funds Novo Ventures RA Capital Rock Springs Capital Tekla Capital Management | undisclosed |
